bpd.fyi — BPD Treatment Self-Advocacy (Patient-Run)

You Are Not Fundamentally Broken

2026-04-10T00:00:00+00:00

I used to believe no one should get close to me.

Not because I didn’t want connection — I did. But because I thought I would keep hurting people and that they would keep hurting me.

If my emotional intensity hurt people, then withdrawing felt responsible. Ethical. And safe.

Toxic shame can convince you that you are the problem — not that something is happening to you.

DBT’s biosocial theory says emotional vulnerability has biological roots. Some nervous systems are simply more sensitive. Emotions hit harder. They last longer. Regulation is harder.

When I began researching what that biology might be, I found work suggesting that BPD may involve dysregulation of the endogenous opioid system — the system that helps regulate pain and attachment.

If baseline opioid tone is low, emotional pain isn’t just “big feelings.” It’s amplified.

Attachment doesn’t just feel important. It feels stabilizing.

Loss can feel like a life-or-death emergency.

When my nervous system stabilized with low-dose buprenorphine, I did not become a different person.

I became steady.

Connection felt possible and rejection felt survivable. I could leave something unhealthy without feeling like I would die from it.

I wasn’t a hazard.

I was dysregulated.

People with BPD are often labeled dramatic, manipulative, attention-seeking, medically expensive.

Up to 75% struggle with substance misuse — often trying to regulate unbearable internal states with whatever works.

Many standard psychiatric medications do not target the endogenous opioid system. That may be critical for relieving the intensity of these internal states.

Low-dose buprenorphine is not a first-line treatment. It is not well-studied for BPD. It will not work for everyone.

But ignoring biology while telling people to “try harder” is not enough.

You are not fundamentally broken.

Your behaviors make sense in the context of a dysregulated nervous system.

And dysregulation is treatable.

The Missing Mechanism in BPD

2026-04-10T00:00:00+00:00

I was diagnosed with BPD about six months after one of the worst interpersonal ruptures of my life. I didn’t just feel ashamed. I felt dangerous.

I believed my emotional intensity and reactions made me unsafe to be close to. The safest thing I could do, for everyone, was to withdraw. I was reactive to things other people seemed to handle just fine, and I couldn't predict what would set me off or how I'd react.

I didn’t isolate out of self-pity. I isolated out of responsibility. I truly believed I needed to protect people from me. And I needed to protect myself from them.

That belief wasn't just shame. It was toxic shame — the conviction that I was fundamentally the problem — not that I had one.

It took years, therapy, and eventually a biological model of BPD for me to understand that this belief was a symptom, not a moral truth.

I wasn't dangerous. I was dysregulated.

</a> I Was Already Trying</h2>
I had been in therapy for three years before I was diagnosed with BPD.
My therapist could see that I needed stabilization, so we worked on DBT skills. I learned distress tolerance. Emotion regulation. Interpersonal effectiveness. I practiced them from the start. I wanted them to work.
About a year after my diagnosis, I joined a DBT group because I hoped it would reduce my frequent suicidal ideation and help me get through job interviews without destabilizing. I believed that if I just became more skillful, things would finally click.
Skills helped in some ways. They reduced self-destructive chaos. They gave structure to moments that used to feel unmanageable.
But they didn't change the fact that rejection, failure, or abandonment could completely dysregulate me in ways other people didn't seem to experience. In college, I'd cry for an hour on the train home convinced I'd failed a test, then get the highest score in the class. Years later, with skills, job interviews still felt like walking through hell barefoot — and I'd completely fall apart after a rejection. Relationships were the same way. I kept people at a distance because I assumed they'd leave anyway.
I was doing the best I could. I wanted to improve. And I was trying hard.
</a> DBT Biosocial Theory</h2>
If I was already trying, then the question wasn’t whether I cared enough — or whether I secretly wanted to stay sick.
The question was: what was driving my symptoms and their intensity?
DBT’s biosocial theory says that emotional vulnerability has a biological basis. Some nervous systems are more sensitive. Emotions hit harder. They last longer. Impulses are harder to restrain. Regulation is more difficult.
DBT starts from the position that you're already doing the best you can. For me, that meant the problem wasn't that I wasn't trying hard enough. It meant looking at what was happening inside me — not blaming everyone around me for how I felt.
If I was doing the best I could, then I wasn’t a moral failure.
I was dysregulated.
If the problem was dysregulation, I wanted to understand the mechanism.
</a> The Missing Mechanism</h2>
DBT was created before we had a clearer understanding of which specific biological systems might be driving these symptoms, and identifying that biology was never its focus.
I wanted to understand the mechanism.
My research started because I was trying to help lessen my favorite person’s constant dissociation. Since dissociation can also be a symptom of BPD, I kept encountering research that circled back to BPD itself.
Eventually, I read a paper asking whether BPD might involve dysregulation of the endogenous opioid system.
When I read it, I saw a biological explanation that matched not only my experience, but patterns I had witnessed for years in people I care deeply about — the same intensity, the same destructive behaviors, the same attachment desperation, the same unbearable reactions to loss.
People whose lives feel like constant crises and chaos. Sometimes, with skills, more functional chaos — but still chaos — just to feel okay.
If baseline opioid tone is low, emotional pain isn’t just “big feelings.” It is amplified at the level of the nervous system.
If the endogenous opioid system helps regulate social bonding and pain, then attachment doesn’t just feel important — it feels stabilizing.
And if you lose an important relationship, it can feel like a life-or-death emergency. I would feel suicidal when relationships ended — even when I knew they were bad for me.
Behaviors that had once looked dramatic or destructive made physiological sense.
They were attempts to regulate an underpowered system.
That realization changed how I saw myself and understood my behavior.
I was not a fundamentally bad person.
I was a dysregulated person.
</a> What Regulation Changed</h2>
Understanding the mechanism changed how I saw myself.
But the real shift happened when my nervous system began to feel regulated.
Social connection no longer felt inherently dangerous. It felt possible.
About a year after starting medication, I began dating someone. Within the first month, something felt off. For the first time, I could recognize trauma reenactment while I was inside it.
That alone was new.
I tried to end the relationship several times. Eventually, I did. Even though I got pulled back in at times — through invalidation, rewritten history, and doubt — I was still moving differently than I had before. This was the first time I was trying to leave something unhealthy while I was still inside it.
And when it ended, I felt a little sad — but steady. I felt relief.
I didn’t spiral into suicidal ideation. I didn’t feel like my life was over.
It was the first time I ended a relationship before it became catastrophic. The first time I didn’t collapse into abandonment panic.
That experience taught me something no theory could:
I was never inherently dangerous.
I was dysregulated.
And when the dysregulation eased, I could choose differently.
</a> You Are Not Fundamentally Broken</h2>
If you believe no one should get close to you, I understand that belief.
It can feel responsible. It can feel ethical. If your intensity has hurt people, withdrawing can seem like the safest choice — for everyone.
Toxic shame can convince you that you are the problem — not that something is happening to you.
If emotional vulnerability has biological roots, then your reactions are not evidence that you are defective. They are evidence that your nervous system is overwhelmed.
And overwhelmed nervous systems do not need condemnation.
They need regulation.
When my nervous system stabilized with low-dose buprenorphine, I did not become a different person. I did not become less intense, less feeling, less myself.
I became steady.
Connection felt possible and rejection felt survivable. I could make choices from steadiness instead of desperation.
Skills mattered. But skills didn't change how frequently I'd get dysregulated or how strongly I'd react when it happened. They helped me manage what came up — they didn't change how much came up. Medication that targeted the underlying biology did.
But we cannot keep telling people with BPD to “try harder” while ignoring the biology that may be driving their suffering.
People with BPD are often labeled dramatic, manipulative, attention-seeking, medically expensive, difficult.
What if much of that suffering is the predictable result of a dysregulated system that has never been adequately treated?
Up to 75% of people with BPD struggle with substance misuse. Alcohol, opioids, benzodiazepines, cannabis — these are often used in attempts to regulate unbearable internal states with whatever works. This is self-medication in the absence of better support.
Many commonly prescribed psychiatric medications do not directly target the endogenous opioid system. If you feel like standard medication treatments haven't helped you, or have only minimally helped, there may be a biological reason for that.
Low-dose buprenorphine is not a first-line treatment. It is not well-studied for BPD. It is difficult to access. It will not work for everyone.
Dismissing the possibility without investigation leaves people like us stuck in shame and cycling through interventions that do not address the core dysregulation.
We deserve better than blame.
We deserve better than being treated as moral failures.
You are not fundamentally broken.
Your behaviors make sense in the context of a dysregulated nervous system.
And dysregulation is treatable.

Buprenorphine Dampens Social Stress

2026-03-23T00:00:00+00:00

This post discusses Bershad et al. (2015), "Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans," published in Psychoneuroendocrinology.

In 2015, researchers at the University of Chicago gave 48 healthy adults either placebo, 0.2 mg, or 0.4 mg of sublingual buprenorphine and then put them through the Trier Social Stress Test — a standardized lab procedure designed to reliably induce psychosocial stress. Participants had to give a speech in front of interviewers and a video camera, then do mental arithmetic under pressure.

What they found was striking. Both doses of buprenorphine completely blocked the cortisol spike that normally follows social stress. The placebo group showed the expected sharp rise in salivary cortisol during and after the stress task. The buprenorphine groups did not.

Both doses also reduced how threatening participants rated the task before it began and increased their satisfaction with their own performance afterward. This wasn't sedation or impairment — actual task performance was unaffected. Neither dose changed heart rate or blood pressure responses to the stress. The drug specifically dampened the hormonal and subjective experience of social threat, without blunting the ability to function under it.

An important detail: participants on 0.2 mg did not report feeling "high." Only the 0.4 mg group showed increased ratings of feeling high, along with nausea. The stress-dampening effect was present at both doses, but the lower dose achieved it without any subjective drug effect.

</a> What the authors concluded — and why the framing matters</h2>
The paper ends with a suggestion that buprenorphine's stress-dampening properties may contribute to the "non-medical use of opioid drugs." In context, this framing is likely descriptive rather than judgmental — the authors were probably noting that buprenorphine's effects on social stress could help explain opioids' appeal outside of pain treatment. That's a reasonable mechanistic observation.
But the framing carries a cost regardless of intent. When stress relief is positioned as evidence of misuse potential rather than therapeutic mechanism, it shapes how patients who seek that relief are perceived — and whether clinicians think to offer it.
If buprenorphine reduces the cortisol response to social stress, and if people with BPD have a dysregulated endogenous opioid system that amplifies interpersonal threat and distress, then using buprenorphine to reduce that stress response isn't non-medical use. It is treating the condition.
The study was conducted in healthy adults. But the effect it demonstrated — blunting the body's alarm response to social evaluation — maps directly onto one of the most disabling features of BPD: interpersonal hypersensitivity. When every interaction carries the weight of potential rejection, judgment, or abandonment, the stress response isn't just uncomfortable. It's paralyzing.
Reducing that response isn't recreational. It's therapeutic. And framing it otherwise obscures a mechanism that could help explain why low-dose buprenorphine works for some people with BPD in ways that other medications have not.
</a> What this looks like in practice</h2>
I take 0.2 mg of sublingual buprenorphine in the morning and 0.1 mg at night. This is my second time on the medication — I restarted in November 2025 after pausing treatment for over a year to see whether I could manage symptoms through diet and inflammation control alone.
At my current dose, I do not feel high. I don't feel sedated. I don't feel altered. What I feel is a noticeable reduction in how stressful social interaction is.
Before medication, I had to hype myself up for a lot of ordinary interactions. Sending an email could paralyze me. Not because the email was complicated or high-stakes, but because any interaction with another person carried the implicit risk of rejection, judgment, or misunderstanding — and my nervous system treated that risk as a threat.
Now I'm cold-emailing researchers. I'm reconnecting with friends I haven't spoken to in years. I can tolerate rejection. I no longer have to avoid interactions for fear of them dysregulating me.
The Bershad study helps explain why.
If buprenorphine suppresses the cortisol response to social stress at 0.2 mg — the same dose I take each morning — then what I'm experiencing isn't just subjective. There's a measurable physiological mechanism: my body is no longer mounting a full stress response to routine social situations. The threat signal is quieter, and I can act instead of bracing.
</a> What 0.4 mg felt like</h2>
In the study, participants on 0.4 mg reported feeling high and experienced nausea. When I first started buprenorphine in 2022, my doctor started me at 0.5 mg. I had nausea, vomiting, and confusion. I felt altered in a way that was distinctly unpleasant, not therapeutic. Lowering the dose resolved the side effects completely.
This aligns with the study's dose-response pattern. The stress-dampening effect was fully present at 0.2 mg — without the subjective drug effects that appeared at 0.4 mg. More is not better. In my experience, the therapeutic window for BPD-related symptoms is often below the threshold where you’d feel “high,” though this can vary with severity. Some opioid-naive patients may ultimately require higher doses. That said, starting low is important to minimize side effects, especially since meaningful benefits can occur at these lower doses.
</a> Dose timing and duration</h2>
The study administered buprenorphine 90 minutes before the stress task, and peak plasma concentrations occur 90–360 minutes after sublingual ingestion. The cortisol-blocking effect was clearly present during this window.
This has practical implications for split dosing. If I take my morning dose and it reaches effective levels within about 90 minutes, that covers most of the day when I'm likely to encounter social stressors. For my evening dose, timing it roughly 90 minutes before the window I need coverage — rather than right before bed — may provide more meaningful stress-dampening during evening interactions while still supporting overnight regulation.
I'm still optimizing this, and individual pharmacokinetics vary. But the study gives a concrete frame for thinking about when the drug is active, not just whether it's present.
</a> This is a medical use</h2>
BPD involves dysregulation of the systems that govern how we experience social threat, attachment, rejection, and emotional pain. The endogenous opioid system is involved in social bonding, separation distress, and regulation of the HPA axis. Buprenorphine acts on that system. BPD appears to involve dysregulation of that system. Prescribing buprenorphine for people whose lives are organized around avoiding the very stress this drug demonstrably reduces is not off-label curiosity — it is targeting a core mechanism of the disorder.
We don't frame SSRIs for depression as "non-medical use of serotonergic drugs." We don't frame stimulants for ADHD as "non-medical use of amphetamines." When a medication targets the system that's dysregulated, using it to treat that dysregulation is medicine.
People with BPD who find relief from buprenorphine are not chasing a high. They are regulating a system that was never adequately treated by other means.
</a> References</h2>
Bershad AK, Jaffe JH, Childs E, de Wit H. Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans. Psychoneuroendocrinology. 2015;52:281-288. doi:10.1016/j.psyneuen.2014.12.004</a>

What Transdermal Buprenorphine Might Mean for Plural Systems

2026-02-20T00:00:00+00:00

Some people have asked what transdermal buprenorphine would actually do for a plural system.
There is no direct clinical research yet on transdermal buprenorphine in plural systems. What follows is a theoretical model informed by opioid research, dissociation research, and limited anecdotal experience. More evidence is needed.
It does not force integration, erase alters, or merge parts. This medication does not restructure identity on its own. The theory here is about stress regulation, not identity control.
This approach may be most relevant for plural systems who also experience intense emotional spikes, self-harm urges, trauma reenactment, or switching that is frequently triggered by stress. Some of these features are commonly seen in individuals with borderline traits.
For systems who are emotionally stable, switch primarily for functional role differentiation, or do not experience crisis-driven dissociation, the effects are less clear. In those cases, opioid modulation may have a smaller impact or may shift internal dynamics in ways that are currently unpredictable.
If the model is correct, here’s what might change in daily life for some systems:

Switching may feel less sudden or less stress-triggered</li>
Emotional spikes may be less extreme</li>
There may be fewer abrupt shifts into shutdown, dissociative overwhelm, or crisis states</li>
Amnesia gaps or “lost time” may become less frequent or less severe.</li>
Headmates might retain more shared memory of what happens while others are fronting</li>
Co-consciousness may feel easier or more stable</li>
Therapy may feel less destabilizing and more manageable</li> </ul>
The idea is that steadier baseline opioid signaling could reduce the intensity of stress-driven dissociation. It would not remove dissociation or eliminate parts. Instead, it may soften dissociative barriers between parts, making internal communication easier without collapsing the system into one identity.
Because there is no direct clinical research yet on transdermal buprenorphine in plural systems, we don’t fully know what dissociation-related side effects might look like.
Most of what we know about medications that affect the opioid system in dissociative disorders comes from low- and ultra-low-dose naltrexone. Buprenorphine works differently, so the effects may not be the same. What we do know is that changes in dissociation can depend on dose, and starting low and adjusting slowly matters.
If dissociative barriers between headmates become more flexible, some systems might notice:

Increased access to memories that were previously harder to reach</li>
Changes in how clearly parts are aware of one another</li>
Temporary anxiety as internal communication changes</li>
Increased dissociation if the dose is too high</li> </ul>
For this reason, it's important to start with a small, steady dosing and make changes gradually.
Any movement toward integration would remain a therapeutic choice, not something medication imposes.
The goal is more control, more stability, and more internal communication within a system.
If you'd like a more in-depth explanation of the pharmacology and theoretical framework, you can read my longer piece here: Why Transdermal Buprenorphine Might Help in DID and BPD</a>
</a> Anecdote</h2>
A close friend of mine with diagnoses of BPD, fibromyalgia, and self-diagnosed DID or OSDD sought pain management after hearing that I had experienced significant relief from my own BPD symptoms using low-dose buprenorphine. She was prescribed a transdermal buprenorphine patch as part of her pain regimen; her dissociative and borderline diagnoses were not discussed in that context and are not listed on her chart, as doing so would likely have derailed the conversation.
The patch provided meaningful pain relief alongside her existing treatments. It was also associated with reduced dissociation, greater overall emotional stability, and most notably, the complete resolution of the suicidal depression she had been experiencing as part of her BPD.
This isn't a claim that this treatment would work for everyone, but it made me hopeful. I share it in that spirit, in case it offers a small amount of hope to readers navigating similar terrain.

Why Transdermal Buprenorphine Might Help in DID and BPD

2026-02-16T00:00:00+00:00

</a> Contents</h2>

Diagnostic Overlap Between DID and BPD</a></li>
Dissociation as an Opioid-Mediated Protective Mechanism</a></li>
Ultra-Low-Dose Naltrexone and Internal Accessibility</a></li>
When Structural Dissociation Co-Occurs with BPD</a></li>
Why Transdermal Buprenorphine May Help</a></li>
Clinical Implications</a></li>
A Brief Anecdote</a></li>
Changelog</a></li>
References</a></li> </ul>
Note: Plural system (often used as plural systems) is a term used by people who experience more than one distinct internal individual, identity, or self-state within a single body. These internal individuals—sometimes called parts, headmates, or system members—may differ in age, role, affect, or sense of self, and may be more or less aware of one another. Plural systems include people diagnosed with dissociative identity disorder (DID), other specified dissociative disorder (OSDD), or other dissociative conditions, as well as people who do not identify their plurality as a disorder. 
Additionally, not everyone with a dissociative disorder identifies as plural. Some prefer strictly clinical language. Both perspectives are respected here, and terminology is used descriptively rather than prescriptively. 
In this article, the term plural systems is used descriptively and respectfully, regardless of whether a person identifies their experience as clinical, non-clinical, or somewhere in between. 
This piece is written for two audiences:
For people navigating these diagnoses:

Those diagnosed with DID or OSDD who may not realize they also meet criteria for borderline personality disorder (BPD)</li>
Those diagnosed with BPD who may not realize they are living with structural dissociation</li> </ul>
For clinicians: Those interested in novel, biologically informed approaches to treating severe affective instability and dissociation, including low-dose buprenorphine
</a> Diagnostic Overlap Between DID and BPD</h2>
Even at the level of diagnostic criteria alone, DID and BPD share several core features: nonsuicidal self-injury, dissociation, identity disturbance, affective instability, and trauma-linked interpersonal dysregulation. This overlap is not incidental. It reflects shared underlying neurobiology, particularly involving the endogenous opioid system.1</a> 2</a>
Dissociation is mediated in part by endorphins and endogenous opioids. During inescapable threat, opioid release blunts pain, dampens affect, and allows psychological distance from experience.1</a> 2</a>
Dissociation is not a failure of regulation. It is a solution. It is a protective response that works extremely well under overwhelming conditions. An "overwhelming" condition does not necessarily mean extreme, obvious, or intentional abuse.
Early in life, the nervous system depends on consistent connection and regulation from others. Periods of emotional unavailability, misattunement, or chronic aloneness can exceed a young child's capacity to cope, even when caregivers are doing their best. In these contexts, dissociation can emerge as an adaptive way for the nervous system to manage more than it can integrate at the time.
Many people with structural dissociation do not consciously experience themselves as dissociated. The dissociation is doing its job: keeping traumatic material compartmentalized, reducing conscious distress, and maintaining functional appearance.
As described in the DSM-5-TR:

Most individuals with non-possession-form dissociative identity disorder do not overtly display, or only subtly display, their discontinuity of identity, and only a minority present to clinical attention with discernible alternation of identities.3</a> </blockquote>
This contributes to why DID and other dissociative disorders may be overlooked in clinical settings, particularly when dissociation presents as emotional numbing, shutdown, or identity diffusion rather than overt switching. Even when dissociative disorders are recognized, treatment approaches vary widely, and many clinicians report limited training in working with dissociative presentations.4</a>
</a> Dissociation as an Opioid-Mediated Protective Mechanism</h2>
Endogenous opioids appear to play a central role in maintaining dissociative barriers. Small changes in opioid tone can increase or decrease internal separation, which helps explain why highly dissociative systems are often exquisitely sensitive to pharmacologic interventions that affect opioid signaling. In clinical contexts described as “severe DID,” dosage differences as small as 2 milligrams per day of naltrexone have been reported to determine whether suicidal parts or self-states are accessible in therapy at all.5</a>
This sensitivity has direct clinical implications. In individuals who cannot recall large portions of their life history, even modest opioid blockade may increase memory access and reduce dissociative separation—effects that may or may not be experienced as tolerable or welcome. In these cases, very small starting doses of naltrexone are recommended. As described by Ulrich Lanius, some patients find that even 0.1 mg of naltrexone is excessive, and that doses in the range of 10 micrograms are better tolerated early in treatment (11:20 timestamp).6</a>
</a> Ultra-Low-Dose Naltrexone and Internal Accessibility</h2>
When tolerated, subtle modulation of opioid tone with ultra-low-dose naltrexone (ULDN) has been reported to increase internal accessibility and communication.6</a> Clinically, this can mean that parts or self-states become more co-conscious, memories can be approached without immediate shutdown, and affect becomes tolerable rather than overwhelming. Improvements in attention, body awareness, affect tolerance, and self-regulation have been observed alongside reductions in depersonalization, amnesia, tonic immobility, and self-injurious behavior.6</a>
This shift matters because many trauma-focused therapies rely on dual awareness and sufficient affect tolerance. EMDR, somatic therapies, and attachment-focused interventions require the capacity to remain present while processing traumatic material. When internal communication is severely restricted, these modalities may instead trigger further dissociation or crisis states. Subtle opioid modulation may widen the window of tolerance just enough to make other treatments possible.6</a>
These effects are not universally comfortable. Reported adverse responses include sleep disturbance, increased anxiety or avoidance, transient fear or rage, headaches associated with accessing previously dissociated material, and temporary intensification of attachment needs.6</a> Such reactions are often dose-dependent and may improve with careful titration.
For some plural systems without prominent borderline traits, ULDN alone may be sufficient to support trauma-oriented therapies such as establishing internal safety, attachment repair, EMDR, and somatic approaches.5</a> It is worth noting that ULDN for dissociation is an off-label use, as are many applications of low-dose naltrexone across autoimmune, pain, and neurodevelopmental conditions.7</a> 8</a>
</a> When Structural Dissociation Co-Occurs with BPD</h2>
The picture becomes more complex when structural dissociation co-occurs with BPD. In these systems, increasing internal access may simultaneously increase exposure to intense affect. For some individuals, this can initially heighten anxiety, fear, or anger, particularly if baseline regulation is fragile.6</a> Careful titration and close clinical monitoring are therefore essential. In these cases, opioid stabilization alone may be insufficient; broader affect-regulation strategies may need to be supported concurrently.
In BPD, the nervous system is often under chronic extreme stress. Repeated trauma and affective dysregulation drive massive episodic endogenous opioid release. Over time, the brain appears to become tolerant to baseline opioid signaling, requiring extreme distress to re-activate the system. Converging evidence suggests that individuals with BPD may have chronically low baseline endogenous opioid signaling, with compensatory changes in opioid receptor availability, and that self-injury and extreme distress can acutely stimulate endogenous opioid release and function as regulatory mechanisms.9</a>
At this point, behaviors commonly associated with BPD—nonsuicidal self-injury, high-risk or self-destructive behaviors, trauma reenactment, and chaotic attachment patterns—can be understood as attempts at neurochemical self-regulation. These behaviors reliably trigger endogenous opioid release.9</a> They are not attention-seeking; they are survival strategies in a system that cannot otherwise achieve regulation.
</a> Why Transdermal Buprenorphine May Help</h2>
For extremely sensitive systems, a transdermal buprenorphine patch may offer stabilization that other approaches cannot.
The lowest available patch delivers 5 micrograms per hour continuously. For some extremely opioid-sensitive systems, however, even this may be more than is comfortably tolerated. The same exquisite sensitivity that makes microgram-range naltrexone dosing necessary in highly dissociative systems can apply to buprenorphine as well; a person who finds 10 micrograms of naltrexone meaningful may also respond to buprenorphine at doses below the lowest commercially available patch strength.
Because Butrans-type matrix patches hold buprenorphine dissolved evenly throughout the adhesive layer, with release proportional to the surface area in contact with skin, a smaller piece of patch delivers a proportionally smaller dose.10</a> 11</a> This raises the possibility that a fraction of a 5 mcg/hour patch could provide a sub-threshold starting dose for those who need to begin lower than any manufactured patch allows.
This is an off-label modification. Cutting transdermal patches is not validated or recommended by manufacturers; the delivered dose from a cut piece is approximate rather than exact, and cutting can affect adhesion and the stability of the cut edge. It should only be done under clinical supervision, with the same slow, collaborative titration described for ultra-low-dose naltrexone. But for patients with prominent dissociation who cannot tolerate opioid antagonists—for whom even ultra-low-dose naltrexone increases internal access faster than their regulation can absorb—a cut buprenorphine patch may offer a route to baseline opioid support that would otherwise be inaccessible. Where antagonists remove dissociative barriers, buprenorphine supplies tone; for the antagonist-intolerant, that difference may be what makes opioid-based stabilization possible at all.
Buprenorphine’s pharmacology is unusual. It is a partial μ-opioid receptor agonist, meaning it turns the receptor on enough to provide opioid signaling, but with a built-in ceiling that limits how strong that signal can become. At the same time, it binds tightly to the receptor, which reduces the ability of other opioids—including the body’s own endogenous opioids such as endorphins—to attach and produce large surges of activity.12</a> 13</a>
In practical terms, this creates a steadier baseline rather than sharp spikes followed by crashes. Buprenorphine also blocks κ-opioid receptors, which are strongly implicated in dysphoria, despair, and suicidal ideation.12</a> 14</a>
Together, these effects may stabilize opioid tone while reducing the extreme fluctuations that drive trauma reenactment and crisis-based regulation. Clinically, this may reduce trauma-seeking behavior, soften dissociative barriers without collapsing them, and widen the window of tolerance just enough for therapy to proceed.
Importantly, the delivery method matters. Transdermal buprenorphine is absorbed slowly, reaching peak plasma levels much later than buccal or sublingual formulations, and is designed to provide continuous low-dose exposure over a full week.15</a> This slower, steadier profile may be particularly relevant for highly opioid-sensitive dissociative systems, where rapid receptor engagement and peak-trough effects can be destabilizing.
</a> Clinical Implications</h2>
This is not a claim that buprenorphine cures DID or BPD, or that it is an established first-line treatment. Rather, for a subset of highly traumatized, opioid-sensitive systems—particularly when BPD co-occurs with structural dissociation—pharmacological support of baseline opioid tone may reduce crisis-dependent regulation and establish sufficient capacity for psychotherapeutic work.
For ultra-low-dose naltrexone: Extreme dose sensitivity is common in highly dissociative systems. Some patients cannot tolerate 0.1 mg (100 micrograms), and starting doses as low as 10 micrograms are recommended.6</a> Even small dosage changes—as little as 2 mg per day—can dramatically shift which parts or self-states are accessible.5</a> Titrate slowly and collaboratively, monitoring for increased memory access, shifts in co-consciousness, or emergence of previously inaccessible material. Increased internal access may temporarily heighten anxiety, sleep disturbance, intensified attachment needs, or affective dysregulation.6</a> This may be particularly true in systems where structural dissociation co-occurs with prominent borderline traits. These effects reflect the removal of dissociative barriers rather than direct stabilization.
For buprenorphine: The lowest-dose transdermal patch (5 mcg/hour, applied weekly) provides steady-state delivery with minimal peak-trough fluctuation,15</a> which may be better tolerated than sublingual formulations in highly dissociative systems. Unlike naltrexone, buprenorphine supplies baseline opioid tone rather than removing it, which may create a more supportive foundation—reducing dissociative fragmentation while maintaining internal cohesion. Expected outcomes include greater co-consciousness between parts, reduced compulsive dissociation, less reliance on crisis states for regulation, and improved capacity to engage with trauma-focused therapies.
For clinicians, if a patient reports marked sensitivity to opioid modulation or benefit from ultra-low-dose naltrexone, it is reasonable to hypothesize that dissociation is being pharmacologically mediated. In such cases, a continuously delivered buprenorphine approach may provide steadier baseline regulation than episodic modulation with naltrexone.
For patients, recognizing this mechanism can be unsettling. Dissociation hides itself by design. Understanding how the system regulates does not remove protection—it opens the possibility of safer, less costly ways to remain regulated and connected.
</a> A Brief Anecdote</h2>
I want to end on one brief anecdote, offered not as evidence but as a signal. A close friend of mine with diagnoses of BPD, fibromyalgia, and self-diagnosed DID or OSDD, sought pain management after hearing that I had experienced significant relief from my own BPD symptoms using low-dose buprenorphine. She was prescribed a transdermal buprenorphine patch as part of her pain regimen; her dissociative and borderline diagnoses were not discussed in that context and are not listed on her chart, as doing so would likely have derailed the conversation.
The patch provided meaningful pain relief alongside her existing treatments. It was also associated with reduced dissociation, greater overall emotional stability, and most notably, the complete resolution of the suicidal depression she had been experiencing as part of her BPD.
This is an N=1 experience, not a claim of efficacy or universal response, but it made me hopeful. I share it in that spirit, in case it offers a small amount of hope to readers navigating similar terrain.

</a> Changelog</h2>
June 13, 2026 — Added a note on patch dose accessibility: for extremely opioid-sensitive systems, even the lowest 5 mcg/hour patch may be too much, and because buprenorphine is dissolved evenly throughout the adhesive matrix (with release proportional to surface area), a cut portion of a patch may make a sub-threshold dose accessible. Noted this as an off-label, clinician-supervised option, particularly relevant for patients who cannot tolerate opioid antagonists.
</a> References</h2>

Scaer, R. C. (2001). The neurophysiology of dissociation and chronic disease. Applied Psychophysiology and Biofeedback, 26(1), 73–91. https://doi.org/10.1023/a:1009571806136</a> ↩</a> ↩2</a> </li>

Schore, A. N. (2001). The effects of early relational trauma on right brain development, affect regulation, and infant mental health. Infant Mental Health Journal, 22(1-2), 201–269. https://doi.org/10.1002/1097-0355(200101/04)22:1%3C201::AID-IMHJ8%3E3.0.CO;2-9</a> ↩</a> ↩2</a> </li>

American Psychiatric Association. (2022). DSM-5-TR: Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.). Washington, DC. https://www.psychiatryonline.org/doi/book/10.1176/appi.books.9780890425787</a> ↩</a> </li>

Brand, B. L., Myrick, A. C., Loewenstein, R. J., Classen, C. C., Lanius, R., McNary, S. W., Pain, C., & Putnam, F. W. (2012). A survey of practices and recommended treatment interventions among expert therapists treating patients with dissociative identity disorder and dissociative disorder not otherwise specified. Psychological Trauma: Theory, Research, Practice, and Policy, 4(5), 490–500. https://doi.org/10.1037/a0026487</a> ↩</a> </li>

Lanius, U. F., Paulsen, S. L., & Corrigan, F. M. (2014). Neurobiology and Treatment of Traumatic Dissociation: Towards an Embodied Self. Springer Publishing. https://www.springerpub.com/neurobiology-and-treatment-of-traumatic-dissociation-9780826106315.html</a> ↩</a> ↩2</a> ↩3</a> </li>

Lanius, U. F. (2019). Naltrexone dosing in traumatic stress and dissociative symptoms. Presentation at the Low Dose Naltrexone Research Trust Conference. LDN Research Trust. https://ldnresearchtrust.org/ulrich-lanius-phd-naltrexone-dosing-traumatic-stress-and-dissociative-symptoms-2019-conference-ldn</a>
(See ~11:20 for discussion of extreme dose sensitivity and microgram-range dosing). Also, if you see this post Ulrich Lanius, I'd be very interested to know what you think. You've been the most knowledgable resource I've found on dissociation and the use of naltrexone, at all doses. Thank you for your work on this. ↩</a> ↩2</a> ↩3</a> ↩4</a> ↩5</a> ↩6</a> ↩7</a> ↩8</a> </li>

Toljan, K., & Vrooman, B. (2018). Low-dose naltrexone (LDN)-Review of therapeutic utilization. Medical Sciences, 6(4), 82. https://doi.org/10.3390/medsci6040082</a> ↩</a> </li>

LDN Research Trust. (n.d.). Conditions that are helped by Low Dose Naltrexone (LDN). LDN Research Trust – The Low Dose Naltrexone Charity. https://ldnresearchtrust.org/conditions</a> (Accessed February 11, 2026.) ↩</a> </li>

Nance, M., Stetsiv, K., McNamara, I. A., et al. (2024). Acute, Chronic, and Everyday Physical Pain in Borderline Personality Disorder. Current Psychiatry Reports. 26(5), 240–248. https://doi.org/10.1007/s11920-024-01498-0</a> ↩</a> ↩2</a> </li>

Mundipharma. Norspan (buprenorphine) Transdermal Drug Delivery System — Product Information. https://www.researchreview.com.au/MUND0082PI.pdf</a> (Accessed June 13, 2026.)
(See at bottom of Description section: "The composition of all three strengths is identical except for size. The proportion of buprenorphine in the adhesive matrix is the same in each strength (10% by weight). The amount of buprenorphine released from each system per hour is proportional to the surface area of the system. The skin is the limiting barrier to diffusion from the system into the bloodstream.") ↩</a> </li>

Therapeutic Goods Administration. Australian Public Assessment Report for Buprenorphine (Transtec and additional trade names). Mundipharma Pty Ltd, PM-2014-03891-1-1, 13 December 2016. https://www.tga.gov.au/sites/default/files/auspar-buprenorphine-161213.pdf</a> (Accessed June 13, 2026.)
(See p. 23, Quality Findings: "The composition of patches of all strengths is the same except for physical size. The amount of buprenorphine absorbed per hour is proportional to the surface area of the drug matrix in contact with the skin: the greater surface area of drug containing matrix in the higher strength patches enables a higher rate of drug absorption." The report describes the same matrix transdermal delivery system used in the 7-day Norspan patch.) ↩</a> </li>

Lutz, P.-E., & Kieffer, B. L. (2013). Opioid receptors: Distinct roles in mood disorders. Trends in Neurosciences, 36(3), 195–206. https://doi.org/10.1016/j.tins.2012.11.002</a> ↩</a> ↩2</a> </li>

Adler, J., Mallick-Searle, T., Garofoli, M., & Zimmerman, A. (2024). Frontline Perspectives on Buprenorphine for the Management of Chronic Pain. Journal of Multidisciplinary Healthcare, 17, 1375–1383. https://doi.org/10.2147/JMDH.S449748</a>
(See discussion of mechanism: high-affinity partial μ-agonist with κ antagonism; Schedule III; and PK comparison noting transdermal Tmax ~26 hours vs buccal film Tmax ~2.5–3 hours.) oai_citation:5‡PMC</a> ↩</a> </li>

Yovell, Y., et al. (2016). Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation. American Journal of Psychiatry, 173(5), 491–498. https://doi.org/10.1176/appi.ajp.2015.15040535</a>
Brief summary provided here</a> ↩</a> </li>

Dalal, S., Chitneni, A., Berger, A. A., Orhurhu, V., Dar, B., Kramer, B., et al. (2021). Buprenorphine for Chronic Pain: A Safer Alternative to Traditional Opioids. Health Psychology Research, 9(1), 27241. https://doi.org/10.52965/001c.27241</a>
(See section describing BTDS: prolonged low-dose delivery; 5–20 mcg/h; weekly wear; maximal effect ~3 days; and reports of better tolerability vs sublingual.) oai_citation:4‡PMC</a> ↩</a> ↩2</a> </li> </ol> </section>

Rethinking Prevention in BPD and Substance Use Disorder

2026-02-12T00:00:00+00:00

Near the end of a 2019 talk on low-dose naltrexone, Lanius remarked of trauma patients: “They’re addicted to their own opioids.”1</a>
He was referring to endogenous opioids, the body’s internally produced pain- and stress-regulating neurochemicals. In some individuals with dissociative disorders, trauma reenactment and intense, self-destructive behaviors may stimulate this endogenous opioid system. The behaviors are maladaptive, but the underlying mechanism may be regulatory, as the nervous system seeks relief.
If trauma-related dysregulation involves instability in endogenous opioid tone, the overlap between borderline personality disorder (BPD) and substance use disorders deserves closer examination.
Up to 75% of individuals with BPD will meet criteria for substance use disorder in their lifetime. Alcohol, opioids, and benzodiazepines are frequently reported substances in this population, and all directly or indirectly interact with the opioid system.2</a> Conversely, in one outpatient sample of patients initiating buprenorphine for opioid addiction, nearly 44% exceeded the screening cut-off for borderline personality features.3</a> This degree of overlap suggests shared biological vulnerability.
BPD is frequently framed as a disorder of behavior or motivation. Yet if endogenous opioid dysregulation contributes to affective instability, chronic emptiness, self-injury, and interpersonal crises, these behaviors may represent attempts at neurobiological self-regulation rather than willful noncompliance.2</a>
Some authors have proposed that substance use in BPD may partially reflect attempts to modulate distressing internal states. In opioid use disorder (OUD) treatment settings, case-level reports have described patients preferring to remain on low-dose buprenorphine maintenance because they subjectively feel “normal.”4</a> While such observations do not establish mechanism or indication, they suggest that buprenorphine’s effects may extend beyond withdrawal suppression or craving reduction in a subset of patients.
Full opioid agonists carry escalating tolerance and overdose risk. Buprenorphine, as a partial agonist with a ceiling effect on respiratory depression, presents a different pharmacologic profile and has demonstrated mortality-reducing effects in OUD populations.5</a>
This raises a clinical and public health question worth investigating:
If a subset of individuals with BPD have underlying opioid-system dysregulation, could carefully studied, low-dose buprenorphine intervention improve regulation capacity and reduce progression to high-risk opioid exposure?
Recent legislative changes in the United States have eased restrictions on buprenorphine prescribing. As access expands, there is an opportunity not only to treat OUD, but to consider whether earlier, regulation-focused interventions could reduce vulnerability in high-risk populations.
Reframing BPD through a regulation-first lens does not negate the importance of psychotherapy, skills training, or trauma-informed care. Rather, it recognizes that the ability to use skills depends in part on biological regulatory capacity.
If opioid-system dysregulation is contributing to both BPD symptom expression and opioid vulnerability, prevention efforts may need to begin before the first overdose.
</a> References</h2>

Lanius, U. F. (2019). Naltrexone dosing in traumatic stress and dissociative symptoms. Presentation at the Low Dose Naltrexone Research Trust Conference. LDN Research Trust. https://ldnresearchtrust.org/ulrich-lanius-phd-naltrexone-dosing-traumatic-stress-and-dissociative-symptoms-2019-conference-ldn</a> ↩</a> </li>

Bandelow, B., Schmahl, C., Falkai, P., & Wedekind, D. (2010). Borderline personality disorder: A dysregulation of the endogenous opioid system? Psychological Review, 117(2), 623–636. https://doi.org/10.1037/a0018095</a> ↩</a> ↩2</a> </li>

Sansone, R. A., Whitecar, P., & Wiederman, M. W. (2008). The prevalence of borderline personality among buprenorphine patients. International Journal of Psychiatry in Medicine. https://doi.org/10.2190/PM.38.2.h</a> ↩</a> </li>

Nia, A. B. (2017). Opioid addiction and borderline personality disorder. American Journal on Addictions. https://doi.org/10.1111/ajad.12664</a> ↩</a> </li>

Sordo, L., et al. (2017). Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis. BMJ, 357, j1550. https://doi.org/10.1136/bmj.j1550</a> ↩</a> </li> </ol> </section>

Opioid-System Epigenetics as a Bridge Between Autism and BPD

2026-02-07T00:00:00+00:00

This post is part of a developing series exploring borderline personality disorder through the lens of endogenous opioid regulation, neurodevelopment, and trauma.
Many autistic people, particularly those from groups that are historically underrecognized or mischaracterized in autism research, including women and gender-diverse people, are told later in life that their traits resemble borderline personality disorder (BPD). When autism is recognized, an earlier BPD diagnosis is often dismissed as a misdiagnosis, rather than understood as potentially co-occurring. Sometimes the overlap is explained as “autism plus trauma.” Neither framing fully captures what’s happening.
This post explores a different possibility: that chronic stress and misattunement during autistic development can alter the brain’s attachment- and pain-regulation systems in lasting biological ways, specifically the endogenous opioid system.
From this perspective, overlapping autism and BPD traits are not a contradiction. They are the predictable result of a neurodevelopmental difference growing up in an environment that was not built to meet it.
In recent years, BPD has increasingly been linked to dysregulation of the endogenous opioid system, particularly the κ-opioid receptor (KOR), encoded by the OPRK1 gene</a>.1</a> Molecular studies have found that individuals with BPD show altered DNA methylation patterns in OPRK1, with lower methylation correlating with greater symptom severity and reported childhood neglect. Separate postmortem research in people exposed to childhood abuse has identified hypomethylation in regulatory regions of OPRK1 in brain tissue, alongside reduced receptor expression, suggesting stress-mediated epigenetic adaptation of the opioid system.2</a>
The endogenous opioid system regulates attachment, social bonding, stress buffering, pain perception, and affective stability. It therefore sits at the intersection of trauma and social experience.
Autistic children grow up in environments structured around allistic norms. Even in well-intentioned families, this often means chronic misattunement, sensory overload, social confusion, or emotional invalidation. These experiences may not always be labeled “trauma,” but they can represent sustained stress exposure during sensitive developmental periods. If early life stress is capable of reshaping opioid-system regulation via epigenetic mechanisms, then autistic individuals exposed to chronic misattunement may be biologically more vulnerable to later dysregulation of affect and attachment.
Seen this way, BPD in some autistic people, particularly those who must mask extensively to survive socially, is not simply misdiagnosis, nor purely personality pathology. It may represent the downstream consequence of neurodevelopmental difference interacting with chronic developmental stress, mediated in part through stress-sensitive opioid circuitry.
This does not imply that autism causes BPD. Rather, it proposes that the social environments in which autistic children develop may increase risk for trauma-mediated opioid dysregulation, which in turn contributes to BPD traits in a subset of individuals.
</a> References</h2>

Gescher DM, Schanze D, Vavra P, et al. Differential methylation of OPRK1 in borderline personality disorder is associated with childhood trauma. Molecular Psychiatry. 2024;29:3734–3741. DOI: https://doi.org/10.1038/s41380-024-02628-z</a>.

Evidence linking BPD, childhood trauma, and epigenetic regulation of the endogenous opioid system, particularly involving the κ-opioid receptor gene (OPRK1), is summarized here</a>. ↩</a> </li>

Lutz PE, et al. Epigenetic Regulation of the Kappa Opioid Receptor by Early Life Stress. Biological Psychiatry. 2018;84(10):706–715. DOI: https://doi.org/10.1016/j.biopsych.2017.07.012</a>. PubMed: https://pubmed.ncbi.nlm.nih.gov/28886759/</a>.

Summary: Childhood abuse was associated with KOR (OPRK1) hypomethylation and reduced receptor expression in brain tissue, consistent with stress-mediated opioid system adaptation. ↩</a> </li> </ol> </section>